Lenalidomide for second-line treatment of advanced hepatocellular cancer: A brown university oncology group phase II study

Howard Safran, Kevin P. Charpentier, Andreas Kaubisch, Kalyan Mantripragada, Gregory Dubel, Kimberly Perez, Katherine Faricy-Anderson, Thomas Miner, Yoko Eng, Joel Victor, Angela Plette, Joseph Espat, Pamela Bakalarski, Patti Wingate, David Berz, Denise Luppe, Diane Martel, Kayla Rosati, Santiago Aparo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. MATERIALS AND Methods: Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities. Results: Forty patients were enrolled and were classified according to the Child-Pugh score: 19 were Child-Pugh A, 16 patients were Child-Pugh B, and 5 were Child-Pugh C. Seventeen patients had extrahepatic disease. Grade 4 neutropenia occurred in 1 of 40 patients (2.5%). Grade 3 fatigue (n=3) and rash (n=4) were the most common nonhematologic toxicities attributable to lenalidomide. Six of 40 patients (15%) had a partial response. Two patients (5%) have not progressed at 36 and 32 months. The median progression-free survival was 3.6 months and the median overall survival was 7.6 months. Conclusions: Lenalidomide can be administered to patients with advanced HCC and hepatic dysfunction. Promising, and in a small percentage of patients, durable activity has been demonstrated. Investigations are needed to explore the mechanism of action of lenalidomide in HCC.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume38
Issue number1
DOIs
StatePublished - Feb 2 2015

Fingerprint

Liver Neoplasms
Therapeutics
lenalidomide
Exanthema
Neutropenia
Disease-Free Survival
Fatigue
Disease Progression
Survival

Keywords

  • hepatocellular cancer
  • Lenalidomide
  • sorafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lenalidomide for second-line treatment of advanced hepatocellular cancer : A brown university oncology group phase II study. / Safran, Howard; Charpentier, Kevin P.; Kaubisch, Andreas; Mantripragada, Kalyan; Dubel, Gregory; Perez, Kimberly; Faricy-Anderson, Katherine; Miner, Thomas; Eng, Yoko; Victor, Joel; Plette, Angela; Espat, Joseph; Bakalarski, Pamela; Wingate, Patti; Berz, David; Luppe, Denise; Martel, Diane; Rosati, Kayla; Aparo, Santiago.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 38, No. 1, 02.02.2015, p. 1-4.

Research output: Contribution to journalArticle

Safran, H, Charpentier, KP, Kaubisch, A, Mantripragada, K, Dubel, G, Perez, K, Faricy-Anderson, K, Miner, T, Eng, Y, Victor, J, Plette, A, Espat, J, Bakalarski, P, Wingate, P, Berz, D, Luppe, D, Martel, D, Rosati, K & Aparo, S 2015, 'Lenalidomide for second-line treatment of advanced hepatocellular cancer: A brown university oncology group phase II study', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 38, no. 1, pp. 1-4. https://doi.org/10.1097/COC.0b013e3182868c66
Safran, Howard ; Charpentier, Kevin P. ; Kaubisch, Andreas ; Mantripragada, Kalyan ; Dubel, Gregory ; Perez, Kimberly ; Faricy-Anderson, Katherine ; Miner, Thomas ; Eng, Yoko ; Victor, Joel ; Plette, Angela ; Espat, Joseph ; Bakalarski, Pamela ; Wingate, Patti ; Berz, David ; Luppe, Denise ; Martel, Diane ; Rosati, Kayla ; Aparo, Santiago. / Lenalidomide for second-line treatment of advanced hepatocellular cancer : A brown university oncology group phase II study. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2015 ; Vol. 38, No. 1. pp. 1-4.
@article{5b879290940b4469aff51f2abfff2dbf,
title = "Lenalidomide for second-line treatment of advanced hepatocellular cancer: A brown university oncology group phase II study",
abstract = "Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. MATERIALS AND Methods: Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities. Results: Forty patients were enrolled and were classified according to the Child-Pugh score: 19 were Child-Pugh A, 16 patients were Child-Pugh B, and 5 were Child-Pugh C. Seventeen patients had extrahepatic disease. Grade 4 neutropenia occurred in 1 of 40 patients (2.5{\%}). Grade 3 fatigue (n=3) and rash (n=4) were the most common nonhematologic toxicities attributable to lenalidomide. Six of 40 patients (15{\%}) had a partial response. Two patients (5{\%}) have not progressed at 36 and 32 months. The median progression-free survival was 3.6 months and the median overall survival was 7.6 months. Conclusions: Lenalidomide can be administered to patients with advanced HCC and hepatic dysfunction. Promising, and in a small percentage of patients, durable activity has been demonstrated. Investigations are needed to explore the mechanism of action of lenalidomide in HCC.",
keywords = "hepatocellular cancer, Lenalidomide, sorafenib",
author = "Howard Safran and Charpentier, {Kevin P.} and Andreas Kaubisch and Kalyan Mantripragada and Gregory Dubel and Kimberly Perez and Katherine Faricy-Anderson and Thomas Miner and Yoko Eng and Joel Victor and Angela Plette and Joseph Espat and Pamela Bakalarski and Patti Wingate and David Berz and Denise Luppe and Diane Martel and Kayla Rosati and Santiago Aparo",
year = "2015",
month = "2",
day = "2",
doi = "10.1097/COC.0b013e3182868c66",
language = "English (US)",
volume = "38",
pages = "1--4",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Lenalidomide for second-line treatment of advanced hepatocellular cancer

T2 - A brown university oncology group phase II study

AU - Safran, Howard

AU - Charpentier, Kevin P.

AU - Kaubisch, Andreas

AU - Mantripragada, Kalyan

AU - Dubel, Gregory

AU - Perez, Kimberly

AU - Faricy-Anderson, Katherine

AU - Miner, Thomas

AU - Eng, Yoko

AU - Victor, Joel

AU - Plette, Angela

AU - Espat, Joseph

AU - Bakalarski, Pamela

AU - Wingate, Patti

AU - Berz, David

AU - Luppe, Denise

AU - Martel, Diane

AU - Rosati, Kayla

AU - Aparo, Santiago

PY - 2015/2/2

Y1 - 2015/2/2

N2 - Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. MATERIALS AND Methods: Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities. Results: Forty patients were enrolled and were classified according to the Child-Pugh score: 19 were Child-Pugh A, 16 patients were Child-Pugh B, and 5 were Child-Pugh C. Seventeen patients had extrahepatic disease. Grade 4 neutropenia occurred in 1 of 40 patients (2.5%). Grade 3 fatigue (n=3) and rash (n=4) were the most common nonhematologic toxicities attributable to lenalidomide. Six of 40 patients (15%) had a partial response. Two patients (5%) have not progressed at 36 and 32 months. The median progression-free survival was 3.6 months and the median overall survival was 7.6 months. Conclusions: Lenalidomide can be administered to patients with advanced HCC and hepatic dysfunction. Promising, and in a small percentage of patients, durable activity has been demonstrated. Investigations are needed to explore the mechanism of action of lenalidomide in HCC.

AB - Purpose: To assess the activity and toxicity of lenalidomide for patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. MATERIALS AND Methods: Patients with advanced HCC who progressed on or were intolerant to sorafenib were eligible. Patients received lenalidomide 25 mg orally for 1 to 21 days in a 28-day cycle until disease progression or unacceptable toxicities. Results: Forty patients were enrolled and were classified according to the Child-Pugh score: 19 were Child-Pugh A, 16 patients were Child-Pugh B, and 5 were Child-Pugh C. Seventeen patients had extrahepatic disease. Grade 4 neutropenia occurred in 1 of 40 patients (2.5%). Grade 3 fatigue (n=3) and rash (n=4) were the most common nonhematologic toxicities attributable to lenalidomide. Six of 40 patients (15%) had a partial response. Two patients (5%) have not progressed at 36 and 32 months. The median progression-free survival was 3.6 months and the median overall survival was 7.6 months. Conclusions: Lenalidomide can be administered to patients with advanced HCC and hepatic dysfunction. Promising, and in a small percentage of patients, durable activity has been demonstrated. Investigations are needed to explore the mechanism of action of lenalidomide in HCC.

KW - hepatocellular cancer

KW - Lenalidomide

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84964211517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964211517&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3182868c66

DO - 10.1097/COC.0b013e3182868c66

M3 - Article

C2 - 23648434

AN - SCOPUS:84964211517

VL - 38

SP - 1

EP - 4

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -